Marco Proietti (Institute of Cardiovascular Sciences, University of Birmingham, Birmingham) discusses the SPORTIF Trials and their aim to investigate and compare ximelagatran, the first non-vitamin K antagonist oral anticoagulant, with warfarin in patients with atrial fibrillation. The trial was stopped and the drug never commercialised due to adverse liver events, however there is still a lot of data from the randomised controlled trials in the warfarin arm. Dr Proietti discusses the potential for additional and subgroup analysis performed on this data, particularly his work to identify the potential for bleeding risk and adverse bleeding events in patients with atrial fibrillation and bad anticoagulation control who regularly take a number of non-steroidal anti-inflammatory drugs (NSAIDs).
Filmed at EHRA 2018, Barcelona.
1. What was the background and rationale behind your study? 0:07
2. What were the results you presented at this meeting? 1:21
3. What are the next steps in this area of research over the coming years? 2:49